Molecular Therapeutics Theme 3 Accomplishments

Theme 3: Validate clinical effectiveness of new agents and new protocols in interventional treatment trials

Scientific Accomplishments

In preclinical triple-negative breast cancer (TNBC) models, Drs. Boerner, Polin and Heilbrun, working with Dr. LoRusso, found that poly (ADP-ribose) polymerase (PARP) inhibitors such as veliparib (ABT-888) enhanced the activity of the topoisomerase 1 inhibitor irinotecan (CPT-11). Based on these results, a Phase I clinical trial was performed to examine the tolerability of combined veliparib/ironotecan in advanced solid tumor patients. Following the dose-escalation phase, an expansion cohort was opened to perform further biomarker and genomic correlative studies in two specific TNBC populations with the combined veliparib/irinotecan.

  • Lead researchers - Drs. Boerner, Polin and Heilbrun.
  • Collaborative researcher - Dr. Li

Dr. Gadgeelwas a Principal Investigators on a phase I/II study evaluating CH5424802 (alectinib), a second generation ALK (anaplastic lymphoma kinase) inhibitor in patients with ALK positive NSCLC (non-small cell lung cancer) whose disease had progressed following treatment with the first generation ALK inhibitor crizotinib. Based on the results of the phase II trial, the drug has received ‘breakthrough designation’ by the US FDA.

  • Lead researchers - Dr. Gadgeel

The Latest From Karmanos Cancer Institute

News

Izabela Podgorski, Ph.D. awarded 2022 Charles H. Gershenson Distinguished Faculty Fellowship

Izabela Podgorski, Ph.D., professor of Pharmacology at Wayne State University (WSU) and co-leader of the Prostate Cancer Research Team at Barbara ...

Read More

IN THE NEWS: Karmanos Cancer Institute Expands to Ohio

WJR Dick Haefner, host of WJR's HealthWatch with Dick Haefner, sits down with Gerold Bepler, M.D., Ph.D ., president and CEO, Barbara Ann Karmanos...

Read More

The American Cancer Society awards transportation grant to Karmanos Cancer Institute to facilitate access to cancer care

The American Cancer Society (ACS) recently awarded Barbara Ann Karmanos Cancer Institute $15,000 in transportation grant funding to help alleviate...

Read More
News

Eliminating health disparities around multiple myeloma

Listen Now

ACS CAN Michigan Candid Connection

Listen Now

How Multiple Myeloma affects the African American community

Listen Now